Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Florence Polet1, Cyril Corbet1, Adan Pinto1, Laila Illan Rubio1, Ruben Martherus1, Vanesa Bol2, Xavier Drozak3, Vincent Grégoire2, Olivier Riant3, Olivier Feron1 1Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, B-1200 Brussels, Belgium 2Pole of of Medical Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, B-1200 Brussels, Belgium 3Molecules, Solids and Reactivity (MOST), Institute of Condensed Matter and Nanosciences (IMCN), Université catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium Correspondence to: Olivier Feron, e-mail: olivier.feron@uclouvain.be Keywords: glutamine, serine, PHGDH, metabolism, leukemia Received: August 17, 2015 Accepted: November 16, 2015 Published: November 28, 2015